SCHEMBL1498343

SCHEMBL1498343

CN[C@H]1CC[C@@](F)(S(=O)(=O)c2cc(F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 2/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ CXCR3 P49682 1/20 0.34
▸ HTR6 P50406 1/20 0.33
▸ RORC P51449 4/20 0.33
▸ CETP P11597 3/20 0.32
▸ PSEN1 P49768 2/20 0.32
▸ PSEN2 P49810 2/20 0.32
▸ APH1B Q8WW43 2/20 0.32
▸ NCSTN Q92542 2/20 0.32
▸ APH1A Q96BI3 2/20 0.32
▸ PSENEN Q9NZ42 2/20 0.32
▸ APP P05067 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ SLC18A2 Q05940 1/20 0.32
▸ TRPV4 Q9HBA0 1/20 0.31
▸ S1PR2 O95136 1/20 0.31
▸ FFAR4 Q5NUL3 1/20 0.31
▸ NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1498438 1.00 TACR1 (0.37) TACR1SLC6A4CXCR3HTR6RORC
SCHEMBL12692914 0.90 CETP (0.36) RORCCETPPSEN1PSEN2APH1B
SCHEMBL1498353 0.84 CETP (0.40) RORCCETPPSEN1PSEN2APH1B
SCHEMBL1498351 0.84 CETP (0.40) RORCCETPPSEN1PSEN2APH1B
SCHEMBL12688451 0.83 PSEN1 (0.38) TACR1SLC6A4RORCPSEN1PSEN2
SCHEMBL27896524 0.83 PSEN1 (0.38) TACR1SLC6A4RORCPSEN1PSEN2
Hydrochloric Acid SCHEMBL1498352 0.82 PSEN1 (0.37) TACR1SLC6A4HTR6RORCPSEN1
Hydrochloric Acid SCHEMBL1498354 0.82 PSEN1 (0.37) TACR1SLC6A4HTR6RORCPSEN1
SCHEMBL28801609 0.81 RORC (0.41) RORCCETPSTS
SCHEMBL12688387 0.81 RORC (0.41) RORCCETPSTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
EP-2477963-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Zalicus Pharmaceuticals Ltd. (CA) 2012-07-25 — — EP disclosed
WO-2011035159-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1A TACR1 266/4885SLC6A4 198/4885CXCR3 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback